Skip to main content
Premium Trial:

Request an Annual Quote

Precision Therapeutics CLIA-Certified to Offer Med BioGene's GeneFx Lung Assay

NEW YORK (GenomeWeb News) – Med BioGene today said that its commercial partner, Precision Therapeutics, has been certified to perform Med BioGene's lung cancer test out of Precision's Pittsburgh laboratory.

The test, called GeneFx Lung, is a gene expression test for identifying patients with early stage non-small cell lung cancer who, after surgical removal of their tumor, are at higher or lower risks for mortality. Med BioGene and Precision reached a licensing agreement for the test, previously called LungExpress Dx, in 2011.

Med BioGene, based in Vancouver, British Columbia, said that Precision will have discussions with payors "to better understand the current landscape and the specific needs of relevant payors as they apply to GeneFx Lung." The timing of the launch will be determined based on the discussions.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.